News from the Bench

Discover what’s going on at CST, receive our latest application notes and tips, read our science features, and learn about our products.

Subscribe

Important Ordering Details

Custom Ordering Details: Sections are cut freshly upon ordering. Please allow up to three business days for your product to be processed.

Our U.S. Offices Are Closed

Our U.S. offices are closed in observance of Thanksgiving. We will reopen on Monday, December 1st.

Thank you for your patience.

To get local purchase information on this product, click here

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

Product Description

Each control slide contains formalin fixed, paraffin-embedded MKN45 cells, both untreated and treated with the c-Met inhibitor SU11274, that serve as a control for Phospho-Met (Tyr1234/1235) immunostaining. Western blot analysis was performed on extracts derived from the same cells to verify the efficacy of the SU11274 treatment.

To be used with antibodies: 3077.


Met, a high affinity tyrosine kinase receptor for hepatocyte growth factor (HGF, also known as scatter factor) is a disulfide-linked heterodimer made of 45 kDa α- and 145 kDa β-subunits (1,2). The α-subunit and the amino-terminal region of the β-subunit form the extracellular domain. The remainder of the β-chain spans the plasma membrane and contains a cytoplasmic region with tyrosine kinase activity. Interaction of Met with HGF results in autophosphorylation at multiple tyrosines, which recruit several downstream signaling components, including Gab1, c-Cbl, and PI3 kinase (3). These fundamental events are important for all of the biological functions involving Met kinase activity. The addition of a phosphate at cytoplasmic Tyr1003 is essential for Met protein ubiquitination and degradation (4). Phosphorylation at Tyr1234/1235 in the Met kinase domain is critical for kinase activation. Phosphorylation at Tyr1349 in the Met cytoplasmic domain provides a direct binding site for Gab1 (5). Research studies have shown that altered Met levels and/or tyrosine kinase activities are found in several types of tumors, including renal, colon, and breast. Thus, investigators have concluded that Met is an attractive potential cancer therapeutic and diagnostic target (6,7).


1.  Cooper, C.S. et al. (1984) Nature 311, 29-33.

2.  Bottaro, D.P. et al. (1991) Science 251, 802-4.

3.  Bardelli, A. et al. (1997) Oncogene 15, 3103-11.

4.  Taher, T.E. et al. (2002) J Immunol 169, 3793-800.

5.  Schaeper, U. et al. (2000) J Cell Biol 149, 1419-32.

6.  Eder, J.P. et al. (2009) Clin Cancer Res 15, 2207-14.

7.  Sattler, M. and Salgia, R. (2009) Update Cancer Ther 3, 109-118.



For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
SignalSlide® is a trademark of Cell Signaling Technology, Inc.